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Abstract
Background: Acute kidney injury (AKI) is known to increase mortality in hospitalized cirrhotic patients; therefore
early identification is utmost significance. There are only a few studies evaluating the cut-off level of urine
neutrophil gelatinase-associated lipocalin (uNGAL) for diagnosing AKI and its prognostic value in cirrhotic patients.
We aimed to determine the accuracy of uNGAL as a biomarker for early identification of AKI and to determine the
cut-off level of uNGAL for diagnosing AKI in hospitalized cirrhotic patients; and (2) to explore the association of
30-day liver-related mortality with uNGAL level.
Methods and Material: We prospectively enrolled cirrhotic patients admitted at the King Chulalongkorn Memorial
Hospital during May 1, 2011 to Dec 31, 2013. UNGAL levels were measured within 24 h after admission. Clinical and
laboratory data were obtained. Patients were followed up to 30 days.
Results: Of 137 cirrhotic hospitalized patients, 121 cirrhotic patients (88.3 %) with AKI-prone conditions were
included with mean age of 57.3 ± 14.7 years. Thirty-five patients (29 %) developed AKI within 72 h of admission. The
causes of AKI were prerenal azotemia (68.6 %), acute tubular necrosis (25.7 %), hepatorenal syndrome (5.7 %),
respectively. The mean uNGAL level was significantly higher in the patients who developed AKI compared with
those who did not (290.6 ± 356.3 vs. 54.4 ± 73.7 ng/mL; P = 0.0001). The AUC of uNGAL for diagnosing AKI was 0.83
(95 % [CI]: 0.76–0.91) with the optimal cut-off level of 56 ng/mL, providing 77.1 % sensitivity and 73.3 % specificity.
Fourteen percent of subjects died during the 30-day follow-up period. The mean uNGAL levels were significantly
higher in the mortality group. The AUC of uNGAL in predicting mortality was 0.75 (95 % [CI]: 0.66–0.85), with a best
cut-off level of 72 ng/mL providing 70.6 % sensitivity and 69.2 % specificity. However, in multivariate logistic
regression analysis, uNGAL is not an independent factor for 30-day liver-related mortality prediction.
Conclusions: uNGAL is a valid marker for the early detection of AKI in hospitalized cirrhotic patients with AKI-prone
conditions; however, its level could not independently predict 30-day liver-related mortality.
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Background
Patients with cirrhosis frequently require hospitalization.
Acute kidney injury (AKI) is a common complication
occurring up to 20 % in hospitalized cirrhotic individuals
[1] and associated with four-fold increased risk of mor-
tality [2]. In clinical practice, serum creatinine and urine
output are used as indicators of renal dysfunction, des-
pite their known limitations, especially in advanced cir-
rhotic group [3–5]. Serum creatinine does not only
reflect the renal dysfunction but also the degree of liver
dysfunction and malnutrition [4]. Moreover, the rising of
serum creatinine lags behind the onset of AKI at least
24 h, which limit its sensitivity and previous study found
that the severity of renal injury associated with mortality
in hospitalized cirrhotic patients so prompt diagnose and
provide early treatment are utmost significance [6, 7].
Urine neutrophil gelatinase-associated lipocalin (uNGAL)
has emerged as a potential diagnostic biomarker for AKI. It
is a 25-kD polypeptide that is upregulated and secreted in
an early stage of AKI [8]. In experimental and clinical stud-
ies, uNGAL has been extensively investigated in range of
clinical settings [9–13]. Recent studies have focused on the
utility of this marker in cirrhotic patients. However, most
studies investigated in patients who had renal injury before
admission demonstrating that uNGAL could differentiate
between subtypes of renal injuries including acute tubular
necrosis (ATN), hepatorenal syndrome (HRS), and prerenal
azotemia (PRA) [14–16]. Only a few studies investigated
this marker for AKI that developed during admission as fol-
lows: Slack, A. J. et al. demonstrated that uNGAL was sig-
nificantly higher in AKI versus non-AKI but their cohort
recruited only small number of samples [17]. The other
study (Belcher, J. M et al.) used this marker to differentiate
ATN versus others (HRA, PRA) [18]. However, there was
no study investigated the cut-off level of this marker for
diagnosing new-onset AKI during admission.
In term of prognostic value of uNGAL, only three
studies so far investigated about its mortality prediction
and demonstrated mix of results. Verna, E. C. et al.
showed that uNGAL was an independent in-hospital
mortality predictor in patients who had renal injury
prior to admission [15]. Barreto, R. et al. showed that
uNGAL was an independent 3-month mortality predictor
in AKI with bacterial infection. In contrast, Gungor, G.
et al. demonstrated that uNGAL could not predict 90-day
mortality in cirrhotic patients with HRS [19]. Further
study is needed to verify this association in hospitalized
patients with new-onset AKI and focused on liver-related
mortality.
Therefore, we performed a cohort study of hospital-
ized adult cirrhotic patients with AKI-prone conditions.
We aimed: (1) to determine the accuracy of uNGAL as a
biomarker for the early identification of AKI and to de-
termine the cut-off level of uNGAL for diagnosing AKI
in adult hospitalized cirrhotic patients; and (2) to ex-




This was a prospective study of adult cirrhotic patients
who admitted with AKI-prone conditions. All patients
had normal baseline serum creatinine within 3 months
prior to admission and were enrolled during May 1, 2011
to Dec 31, 2013 at tertiary-care, King Chulalongkorn
Memorial hospital. One hundred and thirty-seven patients
with cirrhosis, aged more than 18 years, were admitted
during the study period. Exclusion criteria were chronic
kidney disease, or previous liver or kidney transplantation.
The diagnosis of cirrhosis was based on a combination of
clinical, biochemical and imaging assessments (ultrasound/
computed tomography/magnetic resonance imaging) or
liver biopsy.
Clinical data included demographics, cause of cirrhosis,
Child-Pugh score, MELD score, use of vasoactive drug,
blood transfusion, and length of hospital stay, together with
laboratory data included liver function test, complete blood
count, coagulogram, and blood culture were collected
within 72 h after admission. Patients had urine collection
upon enrollment (within 24 h after admission) and at the
subsequent 24 h for uNGAL measurements. Blood samples
were drawn for serum creatinine upon enrollment and at
24, 48 and 72 h. Patients were prospectively followed up for
mortality assessments to 30 days. The mortality causes were
liver-related conditions including liver-related infection,
HRS, gastrointestinal bleeding, hepatic encephalopathy,
liver failure, and hepatocellular carcinoma.
This study was approved by the institutional review
board (IRB. number 357/55) of the Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand, and all par-
ticipants provided permission for their medical informa-
tion to be used for research purposes. Written informed
consent was obtained from all participants.
Operational definitions of AKI-prone conditions
1. Volume depletion, e.g., gastrointestinal (GI)
bleeding, GI fluid loss, over-diuresis, excessive fluid
loss in patients with ascites treated with diuretics,
large-volume paracentesis [1, 20–22].
2. Bacterial infections, such as spontaneous bacterial
peritonitis (SBP), pneumonia, urinary tract infection
(UTI), skin and soft tissue infections, hepatobiliary
infection, spontaneous bacteremia as defined by
standard diagnostic criteria for each specific
infection.
3. Recent exposure to nephrotoxic agents,
e.g., NSAIDs, contrast agents.
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4. Acute decompensated cirrhosis, e.g., hepatic
encephalopathy, variceal bleeding, SBP and HRS.
Definitions of kidney disease
AKI was defined according to the Acute Kidney Injury
Network (AKIN) criteria as an increase in serum cre-
atinine ≥ 0.3 mg/dL or 50 % from baseline within 48 h
[3]. Renal ultrasound was performed to exclude struc-
tural urinary tract obstruction. PRA was diagnosed in
patients who had history of volume depletion together
with urine sodium less than 20 mEq/L and a FeNa <1 %,
and return of serum creatinine to baseline after volume
replacement within several days. HRS was defined by the
current standard definition for cirrhosis [23]. ATN was
diagnosed in patients who had volume depletion or
nephrotoxic agent exposure together with urine sodium
more than 40 mEq/L and FeNa >2 % [24].
Measurement of uNGAL
Urine samples for uNGAL testing were immediately
centrifuged at 1500 rpm for 10 min, and the supernatant
was stored at −70 °C for batched analysis. UNGAL was
measured by chemiluminescent microparticle assay
using an ARCHITECT platform (Abbott Diagnostics
Inc., Abbott Park, IL, expressed as ng/mL).
Statistical analysis
Categorical data were reported as counts and percent-
ages and compared using Fisher’s exact test. Continuous
variables were expressed as the mean and standard devi-
ation (SD). Comparisons between groups were per-
formed by the independent samples t test for the values
with normal distributions and by the Mann–Whitney
(Wilcoxon rank) test for the continuous variables
without normal distributions. Normal distribution was
determined using the Kolmogorov–Smirnov test. The
chi-square test, Fisher’s exact test, and one-way repeated
measures analysis of variance (ANOVA) were used as
appropriate. All P-values were 2-sided, and P < 0.05 was
considered significant. The area under the curve (AUC)
for each receiver operating characteristic curve was used
to quantify the capacity of uNGAL to diagnose AKI and
predict the mortality. Receiver operating characteristic
(ROC) curves was performed to determine the optimal
cut-off values, sensitivity and specificity. To find the op-
timal threshold point from ROC curve, we used the
Youden index criterion. These cutoffs were used in
multivariate logistic regression modeling for mortality
prediction. Univariate and multivariate logistic regres-
sion models were used to evaluate the relationship be-
tween uNGAL and the mortality. SPSS for Mac (version
19.0; SPSS Inc., Chicago, IL, USA) was used for statis-
tical analysis.
Results
Baseline characteristics of patients
Of 137 cirrhotic patients who were admitted during the
study period, 121 cirrhotic patients (88.3 %) with AKI-
prone conditions were included (Fig. 1) and their base-
line clinical and laboratory data were detailed in Table 1.
The mean age of the patients was 57.3 ± 14.7 years, and
62 % were male. Underlying etiologies of liver injury
were chronic hepatitis B/C (52.1 %), alcoholic cirrhosis
(26.4 %), cryptogenic cirrhosis (11.6 %), NASH (5.8 %),
and autoimmune hepatitis (4.1 %), respectively. The
MELD score was 14.9 ± 5.7. Almost 80 % of patients
were Child-Pugh B and C. Baseline serum creatinine was
0.9 ± 0.3 mg/dL. Thirty-five cirrhotic patients (29 %)
Fig. 1 The diagram of inclusion criteria of cirrhotic patients with AKI–prone condition
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developed AKI within 72 h after admission. In compari-
son of AKI versus non-AKI subgroup, there was no sig-
nificant difference in baseline clinical data including
Child-Pugh score and MELD score except for higher
proportion of ascitic patients was observed in AKI group
(71.4 % versus 50.0 %, P = 0.03). In term of laboratory
data, only ALP (212.9 ± 134.2 U/L versus 142.9 ± 88.7 U/L,
P = 0.001) and platelet (170.3 ± 197.4/103uL versus 111.3 ±
63.8/103uL) were significantly higher in AKI compared with
non-AKI group. Other markers were not significantly dif-
ferent between groups. Of 121 patients with AKI-prone
conditions, 64 (53 %) had bacterial infections which were
SBP in 16, bacteremia in 14, UTI in 11, hepatobiliary infec-
tion in 10, skin and soft tissue infection in 7, respiratory
tract infection in 6 cases, respectively (Table 2). The
remaining of 57 cirrhotic patients with AKI-prone
conditions (47 %) were hospitalized due to GI bleed-
ing (n = 32; 26.4 %), acute decompensation from
hepatic encephalopathy (n = 15; 12.4 %), hypovolemia
from diuretic overdose (n = 6; 5 %) and hypovolemia
post abdominal paracentesis (n = 4; 3.3 %).
uNGAL and the diagnostic value
Our study measured uNGAL twice, first within 24 h after
admission (median uNGAL = 41.2 ng/mL) then at the 24-h
interval (median uNGAL= 48.4 ng/mL). The correlation of
both values was excellent (r = 0.89, P < 0.001). Therefore;
we used only the first measurement level to analyze its early
diagnostic utility.
For diagnosing AKI, the baseline uNGAL level upon ad-
mission was significantly higher in AKI than non-AKI sub-
group (290.6 ± 356.3 vs. 54.4 ± 73.7 ng/mL; P = 0.0001).
Previous study showed that uNGAL level might be in-
creased due to UTI [25, 26]. Our subjects were further cat-
egorized according to the presence or absence of UTI as
well as other bacterial infections. Patients with UTI (n = 11)
Table 1 Patient characteristics at baseline categorized by the presence or absence of AKI
Variables Total No AKI AKI P
Mean ± SD (n = 121) (n = 86) (n = 35)
Age (years) 57.3 ± 14.7 56.4 ± 14.7 59.6 ± 14.8 0.27
% Male 75 (62 %) 52 (60.5 %) 23 (65.7 %) 0.59
Cause of cirrhosis 0.74
-Chronic hepatitis B/C 63 (52.1 %) 44 (51.2 %) 19 (54.3 %)
-Alcohol 32 (26.4 %) 25 (29.1 %) 7 (20.0 %)
-NASH 7 (5.8 %) 4 (4.7 %) 3 (8.6 %)
-Cryptogenic 14 (11.6 %) 9 (10.5 %) 5 (14.3 %)
-Autoimmune 5 (4.1 %) 4 (4.7 %) 1 (2.9 %)
Child-Pugh 0.20
A 25 (20.7 %) 21 (24.4 %) 4 (11.4 %)
B 55 (45.5 %) 39 (45.3 %) 16 (45.7 %)
C 41 (33.9 %) 26 (30.2 %) 15 (42.9 %)
Ascites 68 (56.2 %) 43 (50.0 %) 25 (71.4 %) 0.03
MELD score 14.9 ± 5.7 14.3 ± 5.9 16.4 ± 5.1 0.08
Serum creatinine 0.88 ± 0.29 0.83 ± 0.29 0.96 ± 0.28 0.05
TB (mg/dl) 4.7 ± 5.1 4.5 ± 4.4 5.2 ± 6.6 0.49
DB (mg/dl) 3.4 ± 4.3 3.2 ± 3.5 4.1 ± 5.8 0.28
AST (U/L) 139.7 ± 250.3 129.9 ± 259.8 163.7 ± 22 0.50
- Median (IQR) 73 (43.5–127) 69.5 (44–119) 82 (35–185)
ALT (U/L) 78.4 ± 174.5 72.6 ± 168.2 92.9 ± 190.38 0.56
- Median (IQR) 34 (24–53) 33.5 (24–52) (25–59)
ALP (U/L) 163 ± 108 143 ± 89 213 ± 134 0.001
INR 1.51 ± 0.77 1.51 ± 0.87 1.53 ± 0.45 0.93
Albumin (g/dl) 2.85 ± 0.86 2.9 ± 0.9 2.7 ± 0.6 0.23
Hemoglobin (g/dl) 10.7 ± 2.4 10.7 ± 2.2 10.6 ± 2.9 0.87
WBC count (103/uL) 9.86 ± 6.2 9.6 ± 6.1 10.4 ± 6.6 0.53
Platelet (/103uL) 128 ± 121 111 ± 64 170 ± 197 0.014
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had significantly higher uNGAL compared with non-UTI
(256.9 ± 432.8 versus 109.3 ± 193.3 ng/mL, P = 0.04),
whereas, patients with infections other than UTI (n = 53)
did not have significant different of uNGAL level with non-
infection group (148.4 ± 260.1 versus 102.8 ± 196.4 ng/mL,
P = 0.28). We excluded UTI patients and performed the
new analysis showing that uNGAL was still significantly
higher in AKI versus non-AKI group (252 ± 295.8 versus
48.2 ± 64.3 ng/mL, P < 0.001) and similar as after excluding
all bacterial infections, AKI group still had significantly
higher uNGAL than non-AKI (130.5 ± 97.2 versus 57.6 ±
74.6 ng/mL, P = 0.007). This finding was also observed in
previous study of cirrhotic patients (25). ROC curve
showed that uNGAL level could be used to diagnose AKI
in hospitalized cirrhotic patients with AKI-prone condi-
tions with the AUC of 0.83 (95 % confidence interval [CI]:
0.76–0.91, p < 0.001) as shown in Fig. 2. The optimal cut-
off value was 56 ng/mL providing 77.1 % sensitivity,
73.3 % specificity, 54 % positive predictive value (PPV),
88.7 % negative predictive value (NPV), respectively
(Table 3). After excluding those with UTI, uNGAL still
showed good diagnostic value for AKI (AUC = 0.84,
95 % CI 0.77–0.92, P < 0.001). In contrast, baseline
serum creatinine performed poorly in diagnosing of
AKI (AUC = 0.58, P = 0.4). In our study, there were
no patients with hepatocellular carcinoma or other re-
lated malignancies which might influence the uNGAL
level. In comparison of cirrhotic patients with cut-off
uNGAL of 56 ng/mL, we found that those patients
with uNGAL ≥56 ng/mL were significantly older, had
higher serum creatinine, higher proportion of AKI
and more number of death rate than those with
uNGAL <56 ng/mL (Table 3).
For AKI-subtype differentiation, a total of 35 hospital-
ized cirrhotic patients who developed AKI, 24 (68.6 %)
were diagnosed with PRA, 2 (5.7 %) with HRS, and 9
(25.7 %) with ATN, respectively. The mean uNGAL level
was higher in the patients with ATN than in those with
HRS and prerenal azotemia, respectively (639.7 ± 532.2
vs. 241.0 ± 41.0 vs. 163.8 ± 156.2 ng/mL, P = 0.001). The
median uNGAL levels of the ATN and non-ATN groups
were 559 and 156 ng/mL, respectively (P = 0.005). At the
optimal uNGAL cut-off value of 136.8 ng/mL, a sensitiv-
ity and specificity of 88.9 % and 80.4 %, respectively, was
achieved for the diagnosis of ATN, with an AUC-ROC
of 0.91 (95 % CI: 0.83–0.98, P < 0.05) (Table 4).
uNGAL and the prognostic value
Seventeen patients (14 %) died during the 30-day follow-
up period. The 30-day mortality rate was significantly
higher in AKI group than those without AKI (31.4 % vs.
7.0 %, P < 0.05). The major causes of death were multiple
organ failures and sepsis. The mean uNGAL level was
significantly higher in the mortality group compared with
the survivor group (217.7 vs. 107.2 ng/mL, P = 0.03). The
AUC (95 % CI) for uNGAL for predicting 30-day mortal-
ity was 0.75 (0.66–0.85, P = 0.001), with a best cut-off
value of 72 ng/mL providing 70.6 % sensitivity and 69.2 %
specificity (Table 5).
We used univariate logistic regression analysis to
evaluate the association of age, clinical variables, labora-
tory values, and biomarkers with 30-day mortality. Age,
the use of vasopressor, positive blood culture, AKI and
uNGAL >72 ng/mL were significantly associated with
30-day mortality, whereas, bacterial infection, blood
transfusion, hypovolemia, length of hospital stay, ascites,
serum creatinine, Child-Pugh class C, and MELD score
were not. These variables with P < 0.2 in univariate logis-
tic regression model including age, presence of bacterial
infection, MELD score, hemoglobin level, length of hos-
pital stay, presence of AKI, uNGAL on admission, vaso-
pressor use and renal replacement therapy were added
into multivariate logistic regression analysis. We found
that uNGAL was not the independent factor to predict
30-day mortality adjusting to other factors (Table 4).
Discussion
This is the first prospective study investigate the cut-off
level of uNGAL for diagnosing new-onset AKI in hospi-
talized cirrhotic patients with AKI-prone conditions.
The data suggest that a single measurement within 24 h
after admission is able to diagnose AKI as we measured
twice 24-hour apart and showed good correlation. This
finding confirms the previous results that were estab-
lished in other patient settings with AKI that could be
conveniently applied in cirrhotic patients [12, 27].
Table 2 Indications of hospitalizations of 121 cirrhotic patients
and the cause of bacterial infections in 64 cirrhotic patients
Variables Total No AKI AKI
Number (%) (n = 121) (n = 86) (n = 35)
1. Bacterial infections 64 (53) 41 (34) 23 (19)
- SBPa 16 (13.2) 10 (11.6) 6 (17.1)
- Bacteremia 14 (11.6) 7 (8.1) 7 (20)
- Urinary tract infection 11 (9.1) 9 (10.5) 2 (5.7)
- Hepatobiliary infection 10 (8.3) 7 (8.1) 3 (8.6)
- Skin and soft tissue infection 7 (5.8) 6 (7) 1 (2.9)
- Respiratory tract infection 6 (5) 2 (2.3) 4 (11.4)
2. No bacterial infections 57 (47) 45 (37.1) 12 (9.9)
- GI bleeding 32 (26.4) 28 (23.1) 4 (0.03)
- Hepatic encephalopathy 15 (12.4) 7 (0.06) 8 (0.07)
- Diuretic overdose 6 (5) 6 (0.05) 0
- Post abdominal paracentesis 4 (3.3) 4 (0.03) 0
SBP*:Spontaneous bacterial peritonitis
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Our study design is different from former studies as
we investigated cirrhotic patients with normal baseline
serum creatinine who developed AKI during admission.
Those patients associated with AKI-prone conditions
that frequently finds in clinical practice. For diagnosing
AKI, our study observed the markedly higher uNGAL in
AKI patients compared with non-AKI, which was con-
sistent with previous study in cirrhotic patients [17]. As
UTI might affect higher uNGAL [25, 26], our study also
confirmed this finding after excluded both bacterial in-
fection and UTI subgroups and re-analysis the data.
uNGAL is a good biomarker for early diagnosis with
high AUC-ROC (0.83) with cut-off value of 56 ng/mL
providing a good sensitivity and specificity. This level
might be used for the early detection of AKI in hospital-
ized AKI-prone cirrhotic patients, for example, those
with bacterial infection, acute decompensated cirrhosis
or GI bleeding, which occurred frequently during admis-
sion. Previous studies validated cut-off level of uNGAL
in other settings including hematopoietic stem cell
transplantation, critically ill and after coronary angiog-
raphy, which were the high risks for AKI. Those studies’
cutoff provided good diagnostic efficacy and were super-
ior to other kidney biomarkers such as urinary kidney
injury molecule-1, liver-type fatty acid-binding protein
[28–30]. Our study extended these observations to spe-
cific group of cirrhotic patients. Former study showed
that the severity of renal injury in hospitalized cirrhotic
patients related with poor clinical outcome and early
treatment could provide better result. Therefore, it is
crucial to early detect AKI with effective marker in order
to provide early intervention [2, 6].
Cirrhotic patients might be complicated with HRS,
which is difficult to distinguish with ATN clinically [31].
Fig. 2 ROC curve present the uNGAL to diagnose AKI in hospitalized cirrhotic patients
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HRS is characterized by marked renal vasoconstriction
with a consequence of reduced glomerular function with
preserved tubular function [32]. Therefore, uNGAL
level should not be high as this marker expresses in
renal tubule [33]. Our study confirmed that uNGAL
was significantly higher in ATN compared with non-
ATN and its level could differentiate ATN from other
subtypes with AUC of 0.91. This finding was consistent
with other previous studies [14, 16]. It is crucial to differ-
entiate between subtypes of AKI because of the difference
in management. HRS is treated with vasoconstrictor, albu-
min infusion and TIPS placement, whereas; ATN should
be treated with renal replacement therapy.
In term of the early predicting outcome of this marker,
there were few recent studies investigated in cirrhotic
patients showing that uNGAL was the independent fac-
tor to predict mortality in different settings [15, 34],
whereas the other study was not [19]. Our study found
that uNGAL was significantly higher in 30-day mortality
group compared with survival group and performed well
in predicting the outcome with AUC value of 0.75. This
AUC was comparable to previous cohort [19]. However,
after adjusting to other factors in multivariate logistic re-
gression model, uNGAL was not an independent factor
associated with the 30-day mortality. This finding dif-
fered from previous studies in cirrhotic patients and
might be contributed to the adjusting factors that we in-
cluded in the multivariate model and the more focus for
only liver-related mortality. The severity of Child-Pugh
grading did not significantly predict death in our study;
this finding may be explained that the major causes of
death in our cirrhotic patients were not liver failure. Pre-
vious study by Moreau R and colleagues showed that cir-
rhotic patients with acute on chronic liver failure
(ACLF) had 28-day mortality rate of 33.9 %[35] which
was similar to our study, reporting the 30-day mortality
rate of cirrhotic patients with AKI of 31.4 %. In addition,
the higher numbers of major organs failures was a good
Table 3 Patient characteristics at baseline categorized by the uNGAL cut off level of 56 ng/mL
Variables Total uNGAL <56 ng/mL uNGAL ≥56 ng/mL P
% or mean ± SD (n = 121) (n = 71; 58.7 %) (n = 50; 41.3 %)
Age (years) 57.3 ± 14.7 54.7 ± 13.8 61.0 ± 15.3 0.02*
% Male 75 (62 %) 46/71 (65 %) 29/50 (58 %) 0.45
Ascites 68 (56.2 %) 37/71 (52 %) 31/50 (62 %) 0.28
MELD score 14.9 ± 5.7 14.6 ± 6.2 15.4 ± 5.0 0.44
Serum creatinine 0.88 ± 0.29 0.82 ± 0.27 0.97 ± 0.32 0.006*
TB (mg/dl) 4.7 ± 5.1 4.3 ± 4.4 5.2 ± 6.2 0.34
DB (mg/dl) 3.4 ± 4.3 3.1 ± 3.4 3.9 ± 5.4 0.29
AST (U/L) 139.7 ± 250.3 148 ± 283 128 ± 196 0.66
ALT (U/L) 78.4 ± 174.5 74 ± 180 84 ± 168 0.76
ALP (U/L) 163.1 ± 108.1 155 ± 98 174 ± 121 0.35
INR 1.51 ± 0.77 1.4 ± 0.3 1.7 ± 1.1 0.12
Albumin (g/dl) 2.85 ± 0.86 2.8 ± 0.7 2.9 ± 1.0 0.75
Hemoglobin (g/dl) 10.7 ± 2.4 10.7 ± 2.5 10.7 ± 2.2 0.89
WBC count (103/uL) 9.86 ± 6.2 9.9 ± 6.1 9.8 ± 6.3 0.94
Platelet (/103uL) 128 ± 121 113 ± 66 146 ± 169 0.16
Presence of bacterial infection (%) 64/121 (52.8 %) 34/71 (48 %) 30/50 (60 %) 0.19
Length of stay (days) 9.9 ± 9.7 9.1 ± 9.6 11.0 ± 9.9 0.29
No AKI (%) 86/121 (71 %) 63/71 (89 %) 23/50 (46 %) 0.008*
Death (%) 17/121 (14 %) 5/71 (7 %) 12/50 (24 %) <0.0001*
*P < 0.05
Table 4 The discriminative value of uNGAL
uNGAL (ng/mL) AUC 95 % CI P Cut-off ng/mL Sensitivity (%) Specificity (%) LR+ LR-
AKI vs non-AKI 0.83 0.76–0.91 <0.001 56 77.1 73.3 2.85 0.32
ATN vs non-ATN 0.91 0.83–0.98 <0.001 136.8 88.9 80.4 4.54 0.14
30-day mortality vs survival group 0.75 0.66–0.85 0.001 72 70.6 69.2 2.29 0.42
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predictor of higher mortality rate in cirrhotic patients
with ACLF [35]. Recent study showed that the precipi-
tating factors from hepatic or extrahepatic causes may
influence on the difference of ACLF clinical course and
prognosis [36].
There were some limitations in our study. First, AKI
was diagnosed by AKIN criteria that based on serum
creatinine, which is underestimated in cirrhotic patients
and might be inaccurate. However, serum creatinine is
the marker that is the most widely used in clinical prac-
tice. Second, our study contained a relatively small sam-
ple size of AKI, especially the HRS subgroup, which
might limit the interpretation of the differentiation be-
tween subtypes of AKI. Third, our study did not meas-
ure other renal biomarkers for comparison of the
efficacy with uNGAL. Finally, our study lacks of the val-
idation cohort which needs to test in the future.
Conclusion
Our prospective study indicates that uNGAL is a valid
marker for the early detection of AKI in cirrhotic pa-
tients with AKI-prone conditions. With a cut-off value
of 56 ng/mL, it provides an AUC of 0.83, with a sensitiv-
ity and specificity of 77.1 and 73.3 %, respectively. In
addition, its level can differentiate between ATN and
non-ATN subtype. However, this marker did not inde-
pendently predict 30-day liver-related mortality.
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